2 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
Follow Arrhythmia: new trials by email Literature Review of Arrhythmia trials Research Report on Arrhythmia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease GAP-486 (ZP-123), 0.9% Sodium Chloride, USP - Arrhythmia | Phase 2 | Terminated | Wyeth is now a wholly owned subsidiary of Pfizer | 90 | 2005-11-01 | 2007-12-10 |
| Study Evaluating GAP-486 in Heart Rhythm GAP-486 (ZP-123), 0.9% Sodium Chloride, USP - Arrhythmia | Phase 2 | Terminated | Wyeth is now a wholly owned subsidiary of Pfizer | 30 | 2005-11-01 | 2007-12-10 |
Arrhythmias, Cardiac (2) · Syncope (1)
Cardiovascular Diseases (2) · Heart Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Consciousness Disorders (1) · Nervous System Diseases (1) · Neurobehavioral Manifestations (1) · Neurologic Manifestations (1) · Signs and Symptoms (1) · Unconsciousness (1)
Sodium Chloride (2) · rotigaptide (2)
Wyeth is now a wholly owned subsidiary of Pfizer (2)
Canada (2) · United States (2)